Bravecto Chewable Tablet

Bravecto is a globally recognized veterinary medication designed to protect dogs and cats against fleas and ticks for an extended period, typically lasting up to 12 weeks. The product's active ingredient, Fluralaner, represented a significant breakthrough in veterinary science when it was first introduced, providing a more convenient dosing schedule for pet owners compared to monthly treatments.

The brand was originally developed and launched by Intervet, which later became part of Merck Animal Health (known as MSD Animal Health outside the United States and Canada). While the pharmaceutical research and brand development have deep roots in the United States and Germany, the physical manufacturing of the chewable tablets is largely centered in specialized facilities in Austria, though Merck maintains a global supply chain to distribute the product to various international markets.

As of 2024 and beyond, Bravecto remains a flagship product under the MSD Animal Health portfolio. The brand is ultimately owned by Merck & Co., Inc., one of the world's largest pharmaceutical companies. This ownership ensures that Bravecto benefits from extensive research and development resources and a sophisticated global distribution network that reaches veterinarians and pet owners in over 100 countries.